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Everolimus (EVR) is an orally-administered rapamycin analog that selectively inhibits the mammalian
target of rapamycin (mTOR) kinase (mainly mTORC1 and likely mTORC2) and the related signaling
pathway. mTOR is a serine/threonine protein kinase regulating multiple important cellular functions;
dysfunction of mTOR signaling has also been implicated in the pathophysiology of several neurological,
neurodegenerative, developmental and cognitive disorders. EVR is widely used as an anti-neoplastic
therapy and more recently in children with tuberous sclerosis complex (TSC). However, no clear corre-
lation exists between EVR use and development of central side effects e.g. depression, anxiety or
cognitive impairment. We studied the effects of a 3 weeks administration of EVR in mice chronically
treated with betamethasone 21-phosphate disodium (BTM) as a model of depression and cognitive
decline. EVR treatment had detrimental effects on depressive- and anxiety-like behavior while
improving cognitive performance in both control (untreated) and BTM-treated mice. Such effects were
accompanied by an increased hippocampal neurogenesis and synaptogenesis. Our results therefore
might support the proposed pathological role of mTOR dysregulation in depressive disorders and
conﬁrm some previous data on the positive effects of mTOR inhibition in cognitive decline. We also show
that EVR, possibly through mTOR inhibition, may be linked to the development of anxiety. The increased
hippocampal neurogenesis by EVR might explain its ability to improve cognitive function or protect from
cognitive decline. Our ﬁndings suggest some caution in the use of EVR, particularly in the developing
brain; patients should be carefully monitored for their psychiatric/neurological proﬁles in any clinical
situation where an mTOR inhibitor and in particular EVR is used e.g. cancer treatment, TSC or
immunosuppression.
© 2016 Elsevier Ltd. All rights reserved.1. Introduction
Chronic stress has been implicated as a possible factor in the
etiology of psychiatric disorders including anxiety and depression.artment of Science of Health,
ia T. Campanella, 115, 88100However, the speciﬁc relationship between stress depression and
anxiety, remain unclear (Kendler et al., 1999; Mitchell et al., 2003).
Hyperactivation of the hypothalamic-pituitary-adrenal axis is
associated with the development of depressive symptomatology;
this connection was underlined from evidence that depressed pa-
tients often exhibit hypercortisolism (Pariante and Lightman,
2008), while patients undergoing long-term glucocorticoid ther-
apy, often develop psychiatric and cognitive symptoms (Starkman,
2013). Similarly, features of depression/anxiety-like behavior have
E. Russo et al. / Journal of Psychiatric Research 78 (2016) 1e102been observed in laboratory animals following chronic glucocorti-
coid administration. For example, rodents of several strains treated
long-term with corticosterone (CORT) show higher levels of
depression and anxiety (Aiello et al., 2015; Murray et al., 2008;
Sterner and Kalynchuk, 2010) and an impairment in cognitive
performance (Aiello et al., 2015; Sousa et al., 2000). Additionally,
chronic CORT exposure in rodents causes a signiﬁcant neuronal
remodeling in brain regions associated with depression (i.e. hip-
pocampus and amygdala) in agreement with observations of
morphological changes in depressed patients' brain (Campbell
et al., 2004; Gourley et al., 2013). Furthermore, in rodents,
chronic CORT treatment reduces hippocampal neurogenesis (Crupi
et al., 2010), although strain differences were also found (Aiello
et al., 2015; Hodes et al., 2012). According to the ‘neurogenesis
hypothesis’ of depression, a decrease in the production of newborn
hippocampus granule cells is related to the disease pathophysi-
ology (Hanson et al., 2011); however, studies show no direct link
between decreased neurogenesis and onset of depression (Petrik
et al., 2012; Tang et al., 2012).
Everolimus (EVR) is an orally-administered rapamycin analog
that selectively inhibits mTOR kinase activity (mainly mTORC1 and
likely mTORC2) (Hasskarl, 2014; Sarbassov et al., 2006). mTOR is a
serine/threonine protein kinase regulating multiple important
cellular functions; dysfunction of mTOR signaling has also been
implicated in the pathophysiology of several neurological disorders
(Russo et al., 2012; Wong, 2013). EVR is widely used as an anti-
neoplastic therapy and recently in children with tuberous scle-
rosis complex (TSC) (Curatolo and Moavero, 2012; Kotulska et al.,
2013). In humans, it has been observed that EVR treatment may
provide signiﬁcant improvement in memory and psychiatric
symptoms among heart transplant recipients (Lang et al., 2009);
conversely, in renal transplant patients receiving rapamycin treat-
ment, cognitive impairment,was observed (Martinez-Sanchis et al.,
2011). Moreover, no clear correlation was observed between the
use of EVR and side effects such as depression, anxiety or cognitive
impairment (Curatolo andMoavero, 2012; Hasskarl, 2014). Recently
one study has demonstrated that EVR treatment (14 days) had no
inﬂuence on animal behavior and neurogenesis in mice without
any underlying disease (Dubois et al., 2014).
Compared with EVR, the effects of rapamycin on the central
nervous system (CNS) have been better characterized; however,
opposite results have been reported. Subchronic rapamycin treat-
ment resulted in antidepressant-like activity while long-term
treatment increased depressive-like behavior (Cleary et al., 2008;
Russo et al., 2013c). Moreover, rapamycin signiﬁcantly decreased
depressive and anxiety-like behaviors in mice, possibly by stimu-
lating major monoamine pathways in the brain (Halloran et al.,
2012). Rapamycin has shown relevant effects on cognitive perfor-
mance in rodent models (Brewster et al., 2013; Majumder et al.,
2012; Spilman et al., 2010); whereas, systemic inhibition of mTOR
prevents hippocampal neurogenesis (Paliouras et al., 2012; Raman
et al., 2011, 2013).
The involvement of mTOR signaling in major depressive disor-
der (MDD) has been suggested by the recent observation that the
rapid antidepressant effects of ketamine both in animals and in
patients, are associated with mTOR activation (Duman et al., 2012)
and that depressive symptomatology is correlated with mTOR
dysfunction in the prefrontal cortex (Jernigan et al., 2011). More-
over, the inhibitory effect of long-term CORT treatment on mTOR
signaling, in mouse cells (Howell et al., 2011), has been indicated as
a possible mechanism underlying its pro-depressant activity. Based
on this background, we investigated here the effects of EVR treat-
ment on animal behavior and neurogenesis in an animal model of
chronic stress induced by chronic administration of betamethasone
21-phosphate disodium (BTM) in DBA/2 mice.2. Materials and methods
2.1. Animals
Male DBA/2 mice (8 weeks old) were purchased from Charles
River Laboratories s.r.l (Calco, Lecco, Italy). Mice were housed ﬁve
per cage and maintained under stable conditions: humidity
(60 ± 5%), temperature (21 ± 2 C), reversed light/dark (12/12 h)
cycle (light on at 19.00) and libitum access to food and water. All
efforts were made to minimize animal suffering and to use only the
number of animals necessary to produce reliable scientiﬁc data.
Procedures involving animals and their care were conducted in
conformity with the international and national laws and policies
(EU Directive, 2010/63/EU for animal experiments, ARRIVE guide-
lines and the Basel declaration including the 3R concept).
2.2. Experimental design
DBA/2 mice were randomized into 4 groups (n ¼ 20 animals/
group) according to treatment: CTRL group assigned to oral vehicle
(water) for 7 weeks; EVR group orally treated with vehicle for the
ﬁrst 4 weeks and, for the subsequent 3weeks, given oral EVR (5mg/
kg/day; Novartis Pharmaceutical Development, Basel, Switzerland);
BTM group was given oral BTM (0.25 mg/kg/day; Sigma Aldrich,
Milan, ITALY) for 7 consecutive weeks. Finally, the BTM-EVR group
was treated with oral BTM for 7 consecutive weeks and in the last 3
weeks, oral EVRwas added to the BTM treatment (Fig.1A). BTM and
EVRwere given ad libitum in the drinkingwater in bottles protected
from light. Final dilution was calculated on the evidence that mice
drink on average 10 ml/100 g/day; this was further conﬁrmed by
checking the volume drunk by mice (Aiello et al., 2015). EVR (5 mg/
kg/day) and BTM (0.25 mg/kg/day) dosage were chosen according
to previous studies (Aiello et al., 2015; O'Reilly et al., 2010). Mice
were weighted three times a week for the entire duration of the
experiments. Additionally, the mouse coat condition was observed
and scored as previously described (Crupi et al., 2011). A different
group of mice was only treated with EVR and phospho-p70S6 Ki-
nase (Ser371) was measured by western blotting to ascertain
whether drug treatment would inhibit mTOR pathway in the hip-
pocampus (see Supplementary Material S1).
2.3. Behavioral tests
Every experimental group was divided in two subgroups of 10
animals for testing (Test I: Morris water maze group; Test II: All
others paradigms used in the following order: Forced swimming
test; Open ﬁeld arena; Elevated plus maze; Novelty suppressed
feeding); in Test II series, inter-test interval was at least 1 day (range
1e3 days). All tests were carried out with the support of EthoVision
XT8 Software (Noldus, Netherlands) (Aiello et al., 2015).
2.4. Forced swimming test (FST)
The FST has been previously used for measuring the immobility
time (IT) and assessing depressive-like behavior in rodents (Nestler
and Hyman, 2010; Russo et al., 2013c). Mice were placed individ-
ually for 6 min into glass cylinders (height 26.5 cm, diameter
16.5 cm) containing water, maintained at 25 C, as previously
described (Citraro et al., 2015). The IT was scored and analyzed for
the last 4 min (Aiello et al., 2015; Russo et al., 2011b).
2.5. Open ﬁeld test (OFT)
The OFT was a Plexiglas box (50  50 cm) divided into 16
squares. The center of the box was deﬁned by 4 squares. The
E. Russo et al. / Journal of Psychiatric Research 78 (2016) 1e10 3following variables were measured: time spent in center, number
of center entries, total distance moved and mean velocity during a
10 min test (Citraro et al., 2014; Crupi et al., 2011). Reduced
exploratory (locomotor) activity in the OFT is usually considered as
a measure of increased levels of anxiety/emotionality and vice-
versa (Russo et al., 2013b).
2.6. Elevated plus maze test (EPM)
The EPM apparatus consists of two opposing open arms
(45 cm  10 cm) and two opposing closed arms of the same size
with walls 10 cm high. The arms were connected by a central
platform (10  10 cm) as previously described (Russo et al., 2013a).
The number of entries into, time spent on each arm and central
square were scored for 10 min. The shorter the time spent in open
arms and central square, the greater is the number of risk assess-
ments, the higher is anxiety and vice-versa (Crupi et al., 2010;
Russo et al., 2013b).
2.7. Novelty-suppressed feeding test (NSF)
The apparatus used for the test was a plastic box (50 50 cm) as
previously described (Aiello et al., 2015). Twenty-four hours before
behavioral testing, food was removed from the home cage. At the
time of testing, a single pellet of food (regular chow) was placed in
the center of the box as previously reported (Crupi et al., 2011). The
latency to begin eating was used as an index of anxiety-like
behavior (Crupi et al., 2011).
2.8. Morris water maze test (MWM)
Learning and memory performance was assessed using MWM
test (Russo et al., 2013a; Vorhees and Williams, 2006). The appa-
ratus consisted of a circular basin (diameter ¼ 93 cm,
height ¼ 45 cm) ﬁlled with water (approximately 25 C) to a depth
of 24 cm, with a hidden escape platform (diameter ¼ 8 cm) placed
1 cm below the water surface. Mice (n¼ 10/group) were trained for
4 consecutive days, with 4 trials on each day. The single trial
durationwas 60 s(s). MWMwas performed as previously described
(Aiello et al., 2015; Russo et al., 2013a).
2.9. Immunohistochemistry
To label newly-born cells, we used incorporation of the thymi-
dine analogue BrdU into DNA during the S-phase of the cell cycle, as
previously described (Aiello et al., 2015; Crupi et al., 2011). BrdU
was administered intraperitoneally at 150 mg/kg in saline. Mice
were sacriﬁced 2 h after injection. After anesthesia with sodium
pentobarbital (30 mg/kg), mice were transcardially perfused (cold
saline, followed by 4% cold paraformaldehyde in phosphate buff-
ered saline (PBS)). All brains were post-ﬁxed overnight in 4%
paraformaldehyde at 4 C, then cryoprotected in 30% sucrose, and
stored at 4 C. Immunohistochemistry was performed, as previ-
ously described (Aiello et al., 2015; Crupi et al., 2011).
2.10. Golgi impregnation
Golgi impregnation was performed according to the directions
supplied by FD NeuroTechnologies (FD NeuroTechnologies, Ellicott
City, MD, USA). Blocks of brain tissue were placed directly into
solutions A and B, without rinsing, and remained there for 2 weeks
in the dark at room temperature. Forty-eight hours after placing the
blocks in solution C (4 C), the blocks were frozen on dry ice and
stored at 70 C until sectioning. Cryostat sections (100 mm)were cut
and mounted onto gelatinized slides. The tissue had to be staineddark with uniform Golgi impregnation that was uniform
throughout the section, to be selected for the analysis. Neurons
chosen for tracing met the criteria previously described (Aiello
et al., 2015). Cells chosen for analysis had to be well impregnated,
clearly distinguishable from adjacent cells and have continuous
unbroken dendrites. Spines were counted under oil (X100) using
light microscopy, and the entire visible dendritic length measured
by imaging computer program (Axio-Vision, Zeiss). Spine density
was calculated referring to the length of the dendrite (Crupi et al.,
2011).
2.11. Statistical analysis
All statistical procedures were performed using SPSS 15.0.0
software (SPSS Inc., Chicago, Illinois, USA). Comparisons were per-
formed using two-way Analysis Of Variance (ANOVA) followed by
Tukey's post-hoc test. Statistically signiﬁcant differences were
considered at P  0.05.
3. Results
3.1. Coat state and body weight
The measure of the coat state of the animals has been described
as a reliable and well-validated index of a depressed-like state
(Crupi et al., 2010, 2011). Long-term oral BTM treatment induced
both a signiﬁcant deterioration of the coat-state of mice (data not
shown) and a signiﬁcant reduction in body weight (F(1,36) ¼ 7.99;
P < 0.01), starting from the second week of treatment, as shown in
Fig. 1B. Both these parameters were not signiﬁcantly re-established
after EVR oral administration. On the other hand, mice treated with
EVR alone did not differ from control vehicle-treated mice.
3.2. Forced swimming test (FST)
In the FST, long-term BTM treatment had no behavioral effects
(Fig. 1D) whereas oral administration of EVR signiﬁcantly increased
(F(1,36) ¼ 13.24; P < 0.001) the IT both in BTM-treated and vehicle-
treated mice. No signiﬁcant differences were measured between
the two EVR-treated groups. Furthermore, independently from
BTM treatment, a signiﬁcant reduction (F(1,36) ¼ 12.09; P < 0.01) in
total distance moved andmean velocity in both EVR-treated groups
(EVR and BTM-EVR) in comparison to respective control groups
(CTRL and BTM groups, respectively), was observed (Table 1).
3.3. Open ﬁeld test (OFT)
As shown in Fig. 1G and H, in the OFT, the time spent in the
center and the number of entries in the center, were not signiﬁ-
cantly changed by exogenous chronic BTM treatment. EVR admin-
istration, for 3 weeks, signiﬁcantly reduced these parameters
(F(1,36) ¼ 12.41; P < 0.05) both in BTM-treated and vehicle-treated
mice. EVR effects were similar in the two groups. In particular,
EVR chronic treatment was able to reduce the time spent in the
center by ~39% in vehicle-treated mice and ~34% in the BTM-
treated group (Fig. 1G); furthermore, in the EVR group in compar-
ison with the CTRL group, a 47% reduction in the number of entries
in the center was found, whereas in the BTM-EVR group, versus
BTM-group, the percentage decrease was ~55% (Fig. 1H). Chronic
BTM treatment signiﬁcantly reduced, in the OFT, both the total
distance moved and the mean velocity; furthermore, despite BTM
treatment, a signiﬁcant reduction (F(1,36) ¼ 10.19; P < 0.01) was
observed in both parameters in the EVR-treated groups (EVR and
BTM-EVR) in comparison to control groups (CTRL and BTM groups,
respectively) (Table 1).
Fig. 1. (A) Schematic representation of the experimental design. DBA/2 mice were orally administered during 7 weeks with vehicle or betamethasone 21-phosphate disodium (BTM;
0.25 mg/kg/day) in the presence or absence of oral everolimus (EVR; 5 mg/kg/day) during the last 3 weeks. (B) Mice body weight (grams) monitored during the 4 weeks of BTM oral
administration and the 3 weeks of EVR oral treatment. (D) IT in the FST, expressed in seconds (s). (E) Latency to feed in the Novelty Suppressed Feeding Test (NSF), expressed in
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Table 1
Everolimus (EVR) effects on total distance moved (TDM) and mean velocity (MV) in
the forced swimming test, open ﬁeld test and elevated plus maze test.
Groups TDM (cm) MV (cm/s)
Forced swimming test (FST)
CTRL 1815.36 ± 113.96 8.06 ± 0.79
EVR 1275.86 ± 77.96* 4.21 ± 0.22*
BTM 1843.63 ± 69.17 8.45 ± 0.45
BTM-EVR 1397.78 ± 42.30*# 4.45 ± 0.14*#
Open ﬁeld test (OFT)
CTRL 5223.61 ± 192.97 8.83 ± 0.33
EVR 3720.53 ± 142.67* 6.17 ± 0.15*
BTM 3815.53 ± 86.63* 4.94 ± 0.15*
BTM-EVR 2902.54 ± 99.89*# 2.76 ± 0.23*#
Elevated plus maze test (EPM)
CTRL 2591.41 ± 165.40 cm 4.42 ± 0.29 cm/s
EVR 1478.19 ± 103.54 cm* 3.12 ± 0.24 cm/s*
BTM 1637.19 ± 77.08 cm* 3.02 ± 0.21 cm/s*
BTM-EVR 1043.89 ± 28.98 cm*# 1.76 ± 0.21 cm/s*#
Mean velocity (MV; cm/s; Mean ± SEM) and total distance moved (TD; cm;
Mean ± SEM) in the FST, OF and EPM. Data marked with “*” are signiﬁcantly
different (p < 0.01) from CTRL-group. Data marked with “#” are signiﬁcantly
different (p < 0.01) from BTM-group. CTRL: group assigned to oral vehicle (water)
for 7 weeks; EVR: group orally treated with vehicle for the ﬁrst 4 weeks and, for the
subsequent 3 weeks, given oral Everolimus; BTM: group treated with oral BTM for 7
consecutive weeks; BTM-EVR: group treated with oral Betamethasone 21-
phosphate disodium (BTM) only for the ﬁrst 4 weeks and, for the subsequent 3
weeks, oral EVR was added to BTM treatment.
E. Russo et al. / Journal of Psychiatric Research 78 (2016) 1e10 53.4. Elevated plus maze test (EPM)
As shown in Fig. 1L and M, both the time spent in central square
(CS) and the time spent in open arms (OA) were not signiﬁcantly
modiﬁed by exogenous chronic BTM (0.25 mg/kg/day) treatment.
Similarly to the results obtained in the OFT, also in EPM test, EVR
administration, signiﬁcantly reduced these parameters
(F(1,36) ¼ 14.78; P < 0.05) in both BTM-treated and vehicle-treated
mice. Speciﬁcally, in the EVR group, in comparison to CTRL-group,
a reduction of ~30% in the time spent in the central square was
found, whereas in the BTM-EVR group, versus BTM-group, the
percentage decrease of this parameter was ~35% (Fig. 1L).
Furthermore, EVR treatment decreased the time spent in the open
arms by ~34% in vehicle-treated mice, and ~37% in BTM-treated
mice (Fig. 1M). Similarly to the OFT, also in the EPM test, chronic
BTM exposure signiﬁcantly reduced (F(1,36) ¼ 10.80; P < 0.01) both
the total distance moved and the mean velocity; furthermore,
despite BTM treatment, both EVR treated groups (EVR and BTM-
EVR), in comparison to their controls (CTRL and BTM groups,
respectively) showed signiﬁcantly (P < 0.01) lower scores (Table 1).3.5. Novelty suppressed feeding test (NSF)
In the NSF test, a long-term BTM treatment had no effects,
whereas, as shown in Fig. 1E, EVR oral administration signiﬁcantly
increased (F(1,36)¼ 13.52; P < 0.01) the latency to feed in both BTM-
treated and vehicle-treated mice. In particular, in EVR and BTM-
EVR groups, versus their controls, an increase of ~60% and ~66%
in the latency to feed was observed respectively.seconds (s). (G) Time spent in the center in the OFT, expressed in seconds (s). (H) Number o
seconds (s). (M) Time spent in open arms of the EPM, expressed in seconds (s). CTRL: group
the ﬁrst 4 weeks and, for the subsequent 3 weeks, given oral Everolimus; BTM: group trea
methasone 21-phosphate disodium (BTM) only for the ﬁrst 4 weeks and, for the subsequen
TDM: total distance moved; MV: mean velocity. Values plotted are mean ± S.E.M. Data mark
(#) is signiﬁcantly different (P < 0.01) from BTM-treated group.3.6. Morris water maze test (MWM)
As shown in Fig. 2B, BTM chronic treatment caused a signiﬁcant
impairment in learning and spatial memory (F(1,36) ¼ 11.14;
P < 0.01) with a longer latency to ﬁnd the platform during daily
trials starting from day 2. In particular, BTM-treated mice showed a
progressive impairment on experimental days with an increase in
latency to platform ranging from 50 to 86%. Furthermore, as shown
in Fig. 2D, BTM signiﬁcantly reduced (F(1,36) ¼ 9.83; P < 0.01) the
time spent in the former platform quadrant on day 5.
EVR administration signiﬁcantly reduced the latency to ﬁnd the
platform, already starting from day 2, in both BTM-treated and
vehicle-treated mice. Speciﬁcally, EVR-treated mice showed a
progressive improvement on experimental days with a reduction in
latency to platform ranging from 28 to 54% and 32e47% for EVR and
BTM-EVR groups, respectively (Fig. 2B). Furthermore, EVR signiﬁ-
cantly increased (F(1,36) ¼ 10.36; P < 0.01) the time spent in the
former platform quadrant on day 5 (Fig. 2D) in both BTM-treated
and untreated animals. Chronic BTM treatment signiﬁcantly
reduced, both the total distance moved and the mean velocity
during the four experimental days and the probe trial on day 5; EVR
treatment did not signiﬁcantly modify both parameters (Table 2).
3.7. Immunohistochemistry
Chronic BTM and EVR exposure signiﬁcantly (F(1,36) ¼ 8.08;
P < 0.05) increased, both BrdU and DCX-positive cells, in the den-
tate gyrus (DG) of the adult mouse hippocampus (see Fig. 3AeD).
Tracing apical dendrites in DG granule cells also revealed a signif-
icant (F(1,36)¼ 9.24; P < 0.05) increase of spine density number after
administration of BTM and EVR (see Fig. 3EeF).
4. Discussion
The mTOR pathway has been implicated in the pathophysiology
of MDD both in experimental animal models and humans
(Cambiaghi et al., 2013; Jernigan et al., 2011; Russo et al., 2013c) and
more recently it has been indicated as a suitable pharmacological
target for novel antidepressant drug development (Abelaira et al.,
2014). Deﬁcits in mTOR signaling in the prefrontal cortex (PFC) of
rodents and humans contribute to the development of depressive
symptomatology (Abelaira et al., 2014; Jernigan et al., 2011).
Accordingly, recent ﬁndings suggest that the rapid antidepressant
effects of the anesthetic agent ketamine, a selective and potent N-
methyl-D-aspartate (NMDA) glutamate receptor/ion channel
blocker, are strongly related to the activation of mTOR function,
followed by enhanced mTOR-dependent protein synthesis in the
PFC of rats (Duman et al., 2012; Jernigan et al., 2011; Li et al., 2010).
In particular, after ketamine-induced mTOR activation, the increase
in protein synthesis seems to be caused by stimulation of p70S6K
and 4E-BP1. In fact, p70S6K promotes both the synthesis of ribo-
somal unit S6 and the protein translation, which is also augmented
by the hyper-phosphorylation of 4E-BP1. Furthermore, in the PFC, it
was detected that ketamine, through mTOR activation, increases
the synthesis of proteins involved in the process of synaptogenesis
such as PSD95, synapsin I and GluR1 (Li et al., 2010; Scheuing et al.,
2015). In fact, in the PFC of several animal depression models asf entries in the center in the OFT. (L) Time spent in the center of the EPM, expressed in
assigned to oral vehicle (water) for 7 weeks; EVR: group orally treated with vehicle for
ted with oral BTM for 7 consecutive weeks; BTM-EVR: group treated with oral Beta-
t 3 weeks, oral EVR was added to BTM treatment. TR: treatment; IT: immobility time;
ed with “*” are signiﬁcantly different (P < 0.01) from CTRL group; datum marked with
Fig. 2. Everolimus (EVR) effects on cognitive performance in the Morris Water Maze test. (B) Morris water maze results. Latency to platform during daily trials (seconds). BTM
chronic treatment caused a signiﬁcant impairment in learning and spatial memory with a longer latency to ﬁnd the platform during daily trials starting from day 2. EVR
administration for 3 weeks signiﬁcantly reduced the latency to ﬁnd the platform, already starting from day 2, in both BTM-treated and vehicle-treated mice. (D) Morris water maze
results. Time spent in target quadrant in the probe trial on day 5 (%). Chronic BTM signiﬁcantly reduced the time spent in the former platform quadrant on day 5 whereas, EVR
exposure for 3 weeks signiﬁcantly increased this parameter in both BTM-treated and untreated animals. CTRL: group assigned to oral vehicle (water) for 7 weeks; EVR: group orally
treated with vehicle for the ﬁrst 4 weeks and, for the subsequent 3 weeks, given oral Everolimus; BTM: group treated with oral BTM for 7 consecutive weeks; BTM-EVR: group
treated with oral Betamethasone 21-phosphate disodium (BTM) only for the ﬁrst 4 weeks and, for the subsequent 3 weeks, oral EVR was added to BTM treatment. Values plotted are
mean ± S.E.M. Data marked with “*” are signiﬁcantly different (P < 0.01) from CTRL group; datum marked with (#) is signiﬁcantly different (P < 0.01) from BTM-treated group.
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reduction both in the synaptic spine density proteins (Feyissa et al.,
2009) and in the protein levels of mTOR and p70S6K (Jernigan et al.,
2011) was observed. Furthermore, Park et al. (2014) have also re-
ported that several widely prescribed antidepressants including
escitalopram and paroxetine signiﬁcantly increased, in primary
neuronal cell cultures, the levels of phospho-mTOR and its down-
stream regulator phospho-p70S6K. According to the authors, theTable 2
Everolimus (EVR) effects on total distance moved (TDM) and mean velocity (MV) in
the Morris Water Maze test.
Day CTRL EVR BTM BTM-EVR
Total distance moved (cm)
1 410.59 ± 14.08 406.11 ± 8.30 341.75 ± 8.23* 338.27 ± 13.30*
2 352.52 ± 9.42 341.65 ± 23.03 312.01 ± 15.96* 307.51 ± 6.54*
3 335.97 ± 8.18 325.87 ± 7.57 303.78 ± 9.41* 298.40 ± 8.75*
4 303.79 ± 7.21 304.53 ± 16.99 257.39 ± 5.35* 259.93 ± 12.42*
PROBE 294.51 ± 20.64 297.71 ± 1.85 229.41 ± 5.59* 226.89 ± 2.02*
Mean velocity (cm/s)
1 25.15 ± 1.02 22.98 ± 1.02 18.62 ± 0.85* 17.19 ± 0.55*
2 30.09 ± 0.75 27.81 ± 1.35 19.27 ± 0.59* 17.70 ± 0.85*
3 37.22 ± 1.21 35.11 ± 0.63 22.11 ± 0.78* 20.99 ± 0.73*
4 38.18 ± 0.67 36.06 ± 1.29 24.12 ± 0.65* 23.23 ± 1.19*
PROBE 36.06 ± 0.74 34.00 ± 1.17 25.17 ± 1.11 23.34 ± 0.69*
Mean velocity (MV; cm/s; Mean ± SEM) and total distance moved (TD; cm;
Mean ± SEM) in the MWM test during daily trials and probe trial. CTRL: group
assigned to oral vehicle (water) for 7 weeks; EVR: group orally treated with vehicle
for the ﬁrst 4 weeks and, for the subsequent 3 weeks, given oral Everolimus; BTM:
group treated with oral BTM for 7 consecutive weeks; BTM-EVR: group treated with
oral Betamethasone 21-phosphate disodium (BTM) only for the ﬁrst 4 weeks and,
for the subsequent 3 weeks, oral EVR was added to BTM treatment.augmented protein synthesis was matched with an increased
synaptogenesis (Park et al., 2014).
Moreover, it has been shown that intracerebroventricular (i.c.v)
infusion of rapamycin, into the PFC of rats, completely abolishes
ketamine's ability to ameliorate depressive symptoms, suggesting
that the effect of ketamine is mTOR-dependent (Li et al., 2010).
Thus, inhibition of mTOR signaling experimentally would seem to
be pro-depressant; however, there are no data demonstrating the
potential pro-depressant effects of mTOR inhibitors in patients.
Conversely, a clinical study demonstrated that EVR is able to
ameliorate psychiatric symptoms and improve cognitive functions
in heart transplant recipients (Lang et al., 2009).
Our results indicate that 3 weeks of treatment with EVR, at a
dose corresponding to the one used in clinical practice (O'Reilly
et al., 2010), does indeed induce depressive- and anxiety-like
behavior in DBA/2 mice independently from an underlying
stress. However, the DBA/2 mice used in behavioral tests (Costall
et al., 1989; Fish et al., 2010) already show an anxious behavioral
proﬁle in comparison to CD1 strain (Aiello et al., 2015) while
having shorter IT in the FST; these data are in agreement with
previous reports regarding the effects of chronic rapamycin treat-
ment on depressive behavior. Speciﬁcally, acute treatment with
rapamycin had no effects on depressive-like behavior in rodents
(Cleary et al., 2008; Russo et al., 2014) although the development
of an anxiety-like phenotype following systemic administration of
a single dose of rapamycin in rats has recently been demonstrated
(Hadamitzky et al., 2014). In this light, considering our protocol it
could be argued that EVR effects might be due to the last
administration of the drug more than to a chronic effect; although
this point cannot be excluded, generally mTOR inhibitors seem to
Fig. 3. Everolimus (EVR) effects on neurogenesis and synaptogenesis. (A) Cell proliferation in the dentate gyrus (DG) of mice hippocampus: number of BrdU-positive cells. Chronic
BTM and EVR exposure signiﬁcantly increased BrdU-positive cells in the dentate gyrus (DG) of the adult mouse hippocampus. (B) Representative images of BrdU immunohisto-
chemistry for CTRL, EVR, BTM and BTM-EVR groups, respectively. (C) Cell proliferation in the dentate gyrus of mice hippocampus: number of DCX-positive cells. A signiﬁcant
increase in DCX-positive cells, after chronic BTM and EVR administration, in the adult mouse hippocampus, was found. (D) Representative images of DCX immunohistochemistry for
CTRL, EVR, BTM and BTM-EVR groups, respectively. (E) Number of spine density in the dentate gyrus granule cells of mice hippocampus. Long-term BTM and EVR treatment
signiﬁcantly increased the number of spine density in the DG of mice hippocampus. (F) Representative images of spine density number in DG of hippocampus, for CTRL, EVR, BTM
and BTM-EVR groups, respectively. CTRL: group assigned to oral vehicle (water) for 7 weeks; EVR: group orally treated with vehicle for the ﬁrst 4 weeks and, for the subsequent 3
weeks, given oral Everolimus; BTM: group treated with oral BTM for 7 consecutive weeks; BTM-EVR: group treated with oral Betamethasone 21-phosphate disodium (BTM) only for
the ﬁrst 4 weeks and, for the subsequent 3 weeks, oral EVR was added to BTM treatment. Values plotted are mean ± S.E.M. Data marked with “*” are signiﬁcantly different (P < 0.01)
from CTRL group; datum marked with (#) is signiﬁcantly different (P < 0.01) from BTM-treated group.
E. Russo et al. / Journal of Psychiatric Research 78 (2016) 1e10 7have poor effects after acute administration and in any case, the
results observed might represent the sum of chronic and acute
effects. Finally, our administration protocol leads to stable con-
centrations during the day in experimental animals (Russo et al.,
2011a, 2013c). In agreement, sub-chronic exposure to rapamycin
produces antidepressant-like properties in both rats and mice
(Cleary et al., 2008; Russo et al., 2013c) whereas, long-term
rapamycin administration can have either pro-depressant activ-
ity (Russo et al., 2013c) or antidepressive-anxiolytic-like effects(Cambiaghi et al., 2013; Halloran et al., 2012) depending on the
animal model tested.
To date, studies endorse a possible role of autophagy in
depression. However, the signaling pathways of autophagy are very
complex and still not fully understood, in fact, there are several
crucial points where the pathways could be modulated. Therefore,
by virtue of this it is difﬁcult to address the link among mTOR,
autophagy and depression (Jia and Le, 2015). However, it was re-
ported how several antidepressants are able to promote this
E. Russo et al. / Journal of Psychiatric Research 78 (2016) 1e108process in neuronal cells (Gassen et al., 2014; Zschocke et al., 2011).
According to Cleary et al. (2008) the antidepressant-like effect,
observed after sub-chronic treatment with the mTOR inhibitor
rapamycin, could be linked to an induction of autophagy, which is
also regulated by mTOR pathway (Egan et al., 2011).
Dubois et al. (2014) recently showed that EVR orally adminis-
tered for 14 consecutive days did not affect emotional reactivity,
spontaneous activity, learning and memory, behavioral ﬂexibility
and object recognition memory when mice were tested starting
from 7 days after EVR withdrawal. These data are in contrast with
our results both for mouse behavior and memory/learning results.
Considering that we have used the same dose, these differences
might be attributed both to the shorter duration of the treatment
(14 vs. 21 days) and the protocol used, since in our experiments
tests were carried out while mice were still under drug treatment.
Furthermore, it is not possible to exclude that EVR might differ-
entially affect animal behavior also in a genetic background-
dependent manner, similarly to the differences observed for BTM
(Aiello et al., 2015).
Interestingly, EVR treatment had positive effects on cognitive
performance both in BTM-treated and control (vehicle-treated)
mice. This result, together with the above reported data for
depressive and anxiety-like behavior, indicate that EVR effects are
independent of the current background pathology and the drug is
very likely to directly affect CNS function in areas involved in psy-
chological and cognitive functions. Indeed, differences in the EVR
response were observed between BTM and vehicle-treated mouse
groups, however, the experimental outcome was not in contrast
and, even if effectiveness measured as the extent of the modiﬁca-
tion observed in comparison to the respective control group might
be different, EVR had consistent effects, worsening animal behav-
ioral and emotional responses while improving cognitive
performance.
EVR effects are in agreement with some previous results
observed using rapamycin, which ameliorated age-dependent
learning and memory deﬁcits (Majumder et al., 2012) and
decreased cognitive decline associated with neurological disorders
such as status epilepticus (Brewster et al., 2013) and Alzheimer's
disease (Spilman et al., 2010). In this scenario, it is not surprising
that EVR effects on neurogenesis and synaptogenesis in our study
are controversial. Rapamycin's ability to reduce neurogenesis in
rodents has been extensively demonstrated (Paliouras et al., 2012;
Raman et al., 2011, 2013; Russo et al., 2012). In the study by Dubois
et al. (2014), EVR had no effects on neural precursor cell prolif-
eration or vascular component distribution in the hippocampus
after 14 days of treatment. We found a BTM-dependent increase in
neurogenesis and synaptogenesis in the hippocampus, in agree-
ment with our previous ﬁndings (Aiello et al., 2015). EVR itself,
both in BTM and vehicle-treated animals, had similar effects,
increasing neurogenesis and synaptogenesis; however, these ef-
fects were accompanied by a worsening in animal behavior and an
improvement in cognitive performance. These effects are in
contrast both to: 1) our own data, where BTM increased neuro-
genesis and impaired cognitive function without affecting mouse
behavior (Aiello et al., 2015), and 2) previous data supporting a
negative correlation between depression and neurogenesis (Eisch
and Petrik, 2012). Indeed, the correlation between neurogenesis
and neurological/psychiatric diseases/functions is still not well
understood (Eisch and Petrik, 2012; Hanson et al., 2011; Petrik
et al., 2012; Tang et al., 2012). In this light, our results show
once again the difﬁculty in predicting drug effects only from
immunohistochemical results. Overall, EVR-dependent altered
neurogenesis appears in line with the improvement in cognitive
function and in contrast with increased depressive- and anxiety-
like behavior.4.1. Conclusions
In conclusion, we report for the ﬁrst time the potential detri-
mental effects of chronic EVR administration on animal behavior
correlated with depression and anxiety. Furthermore, we conﬁrm
the possible positive effects of this drug on cognitive performance;
this point seems to be linked to an increased neurogenesis and
synaptogenesis in the hippocampus. However, this latter effect
either does not inﬂuence animal behavior or is contributing to its
aggravation. Our results, demonstrating the pro-depressant prop-
erties of EVR both in control and BTM-treated animals, supports
and might extend the knowledge that deﬁcits in the mTOR
signaling are involved in the pathophysiology of depression, further
extending its potential role in anxiety. For the ﬁrst time, we show
that EVR and possibly other mTOR inhibitors might improve
cognitive function or protect from cognitive decline by increasing
neurogenesis. Overall, EVR effects on neurogenesis underline the
need for a critical re-evaluation of this phenomenon in all brain
diseases indicating that alterations in neurogenesis might not be
directly correlated with measurable outcomes such as depression
or cognitive decline. Finally, our ﬁndings suggest caution in the
clinical use of EVR, above all in the developing brain; patients
should be carefully monitored for their psychiatric/neurological
proﬁles in any clinical situation where an mTOR inhibitor will be
used e.g. cancer treatment, TSC or immunosuppression.
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